KRAS and pancreatic neoplasm: For example, RAS mutations in pancreatic cancer are almost exclusively KRAS mutations (greater than 95%), NRAS mutations are the predominant RAS mutations in melanoma (94%), and HRAS mutations are the most common RAS mutations in bladder cancers (54%) [7,8].